These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 15753991)

  • 1. Cancer disease predictive diagnosis: BAT/CD3-positive lymphocytes in cancer patients.
    Hardy B; Raiter A; Rubin M; Sprecher E; Sella A; Flex D; Lelcuk S; Bsharah B; Mishaeli M; Niv Y
    Int J Oncol; 2005 Apr; 26(4):971-5. PubMed ID: 15753991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Construction and in vivo evaluation of an anti-PSA x anti-CD3 bispecific antibody for the immunotherapy of prostate cancer.
    Katzenwadel A; Schleer H; Gierschner D; Wetterauer U; Elsässer-Beile U
    Anticancer Res; 2000; 20(3A):1551-5. PubMed ID: 10928069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BAT mAb induces lymphopoiesis in nude mice.
    Hardy B; Niv Y; Fadaeev L; Raiter A
    Int Immunol; 2005 May; 17(5):615-9. PubMed ID: 15802304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical studies comparing different bispecific antibodies for redirecting T cell cytotoxicity to extracellular antigens on prostate carcinomas.
    Lum HE; Miller M; Davol PA; Grabert RC; Davis JB; Lum LG
    Anticancer Res; 2005; 25(1A):43-52. PubMed ID: 15816517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy.
    Kondo M; Sakuta K; Noguchi A; Ariyoshi N; Sato K; Sato S; Sato K; Hosoi A; Nakajima J; Yoshida Y; Shiraishi K; Nakagawa K; Kakimi K
    Cytotherapy; 2008; 10(8):842-56. PubMed ID: 19016372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD137 enhances cytotoxicity of CD3(+)CD56(+) cells and their capacities to induce CD4(+) Th1 responses.
    Zhu BQ; Ju SW; Shu YQ
    Biomed Pharmacother; 2009 Aug; 63(7):509-16. PubMed ID: 19019623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Purging of epithelial tumor cells from peripheral blood stem cells by means of the bispecific antibody BIS-1.
    Schröder CP; Kroesen BJ; de Leij LF; de Vries EG
    Clin Cancer Res; 2000 Jun; 6(6):2521-7. PubMed ID: 10873108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune stimulatory and anti-tumor properties of anti-CD3 and BAT monoclonal antibodies: a comparative study.
    Hardy B; Kovjazin R; Raiter A; Ganor N; Novogrodsky A
    Hum Antibodies; 1997; 8(2):95-8. PubMed ID: 9289394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased expression of CD40 ligand on activated T cells of patients with colon cancer.
    Büning C; Krüger K; Sieber T; Schoeler D; Schriever F
    Clin Cancer Res; 2002 Apr; 8(4):1147-51. PubMed ID: 11948126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dominance of CD4+ lymphocytic infiltrates with disturbed effector cell characteristics in the tumor microenvironment of prostate carcinoma.
    Ebelt K; Babaryka G; Figel AM; Pohla H; Buchner A; Stief CG; Eisenmenger W; Kirchner T; Schendel DJ; Noessner E
    Prostate; 2008 Jan; 68(1):1-10. PubMed ID: 17948280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor activity and some immunological properties of gammadelta T-cells from patients with gastrointestinal carcinomas.
    Murayama M; Tanaka Y; Yagi J; Uchiyama T; Ogawa K
    Anticancer Res; 2008; 28(5B):2921-31. PubMed ID: 19031935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiolabeled humanized anti-CD3 monoclonal antibody visilizumab for imaging human T-lymphocytes.
    Malviya G; D'Alessandria C; Bonanno E; Vexler V; Massari R; Trotta C; Scopinaro F; Dierckx R; Signore A
    J Nucl Med; 2009 Oct; 50(10):1683-91. PubMed ID: 19759100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Significant differences of lymphocytes isolated from ascites of patients with ovarian cancer compared to blood and tumor lymphocytes. Association of CD3+CD56+ cells with platinum resistance.
    Bamias A; Tsiatas ML; Kafantari E; Liakou C; Rodolakis A; Voulgaris Z; Vlahos G; Papageorgiou T; Tsitsilonis O; Bamia C; Papatheodoridis G; Politi E; Archimandritis A; Antsaklis A; Dimopoulos MA
    Gynecol Oncol; 2007 Jul; 106(1):75-81. PubMed ID: 17433425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulation of antigen-specific T cell response by a non-mitogenic anti-CD3 antibody.
    Li J; Davis J; Bracht M; Carton J; Armstrong J; Gao W; Scallon B; Fung R; Emmell E; Zimmerman M; Griswold DE; Li L
    Int Immunopharmacol; 2006 Jun; 6(6):880-91. PubMed ID: 16644473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Target-dependent T-cell activation by coligation with a PSMA x CD3 diabody induces lysis of prostate cancer cells.
    Bühler P; Molnar E; Dopfer EP; Wolf P; Gierschner D; Wetterauer U; Schamel WW; Elsässer-Beile U
    J Immunother; 2009; 32(6):565-73. PubMed ID: 19483653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD4+CD25+ regulatory T cells in the peripheral blood of patients with breast cancer and non-small cell lung cancer.
    Okita R; Saeki T; Takashima S; Yamaguchi Y; Toge T
    Oncol Rep; 2005 Nov; 14(5):1269-73. PubMed ID: 16211295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human T cells armed with Her2/neu bispecific antibodies divide, are cytotoxic, and secrete cytokines with repeated stimulation.
    Grabert RC; Cousens LP; Smith JA; Olson S; Gall J; Young WB; Davol PA; Lum LG
    Clin Cancer Res; 2006 Jan; 12(2):569-76. PubMed ID: 16428502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potent control of tumor growth by CEA/CD3-bispecific single-chain antibody constructs that are not competitively inhibited by soluble CEA.
    Lutterbuese R; Raum T; Kischel R; Lutterbuese P; Schlereth B; Schaller E; Mangold S; Rau D; Meier P; Kiener PA; Mulgrew K; Oberst MD; Hammond SA; Baeuerle PA; Kufer P
    J Immunother; 2009 May; 32(4):341-52. PubMed ID: 19342971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased frequency of CD4+ cells expressing CD161 in cancer patients.
    Iliopoulou EG; Karamouzis MV; Missitzis I; Ardavanis A; Sotiriadou NN; Baxevanis CN; Rigatos G; Papamichail M; Perez SA
    Clin Cancer Res; 2006 Dec; 12(23):6901-9. PubMed ID: 17145807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone marrow mesenchymal stromal cells (BM-MSCs) from healthy donors and auto-immune disease patients reduce the proliferation of autologous- and allogeneic-stimulated lymphocytes in vitro.
    Bocelli-Tyndall C; Bracci L; Spagnoli G; Braccini A; Bouchenaki M; Ceredig R; Pistoia V; Martin I; Tyndall A
    Rheumatology (Oxford); 2007 Mar; 46(3):403-8. PubMed ID: 16920750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.